NOTE: This activity is available only as part of a paid subscription series; it is not available for purchase as a single, stand-alone activity.
The goal of this program is to improve the management of obesity, hypercholesterolemia, hypertriglyceridemia, and attention-deficit/hyperactivity disorder (ADHD) with novel drug therapies. After hearing and assimilating this program, the clinician will be better able to:
1. Evaluate the efficacy of semaglutide as an adjunct treatment for obesity in patients with type 2 diabetes.
2. Analyze the American College of Cardiology/American Heart Association guidelines for the management of blood cholesterol.
3. Interpret clinical data for novel therapies for hypercholesterolemia and hypertriglyceridemia in adults.
4. Prescribe risk-lowering medications for children with familial hypercholesterolemia.
5. Appraise the efficacy and safety of viloxazine for the treatment of ADHD.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Family-Medicine
- Start Date: 2022-08-09 05:00:00
- End Date: 2022-08-09 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all